Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug spend by 2014.

You may also be interested in...

Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club

The roll-out of Pfizer Inc.’s new personalized non-small cell lung cancer therapy Xalkori blends right in with the prevailing trends in cancer drug launches, proving that six-figure pricing now seems to be the new black in oncology.

Payers Are Preparing For Coming Companion Diagnostics, Medco Notes

Companion diagnostics and biomarkers were the watchwords of the recent ASCO meeting as the cancer community braces for a sea change in treatment. But as more targeted drugs and companion diagnostics make it through the clinical and regulatory arenas, payers will have to grapple with managing the more complex real-world use of these therapies.

Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?

The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts